整形外科診療のためのNSAIDs処方ハンドブック

出版社： 先端医学社
著者：
発行日： 2012-08-20
分野： 臨床医学：外科  >  整形外科学
ISBN： 9784884078270
電子書籍版： 2012-08-20 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

2,860 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

1,430 円(税込)

購入する

商品紹介

本書は、整形外科医が多忙な日常臨床のなかで、NSAIDsの潰瘍リスクを知り、それによって引き起こされる問題をよく理解し、適切な対応を実現できる手助けとなることを目的として企画された。

目次

  • 整形外科診療のためのNSAIDs処方ハンドブック

    ―目次―

    Part 1　疼痛管理におけるNSAIDsの位置づけをみる
    　　　　〜NSAIDs潰瘍の臨床的課題から治療および
    　　　　　予防の意義を知る〜
    　1．疼痛管理の重要性とNSAIDsの位置づけをみる
    　2．NSAIDs潰瘍の臨床的問題の重大性をみる

    Part 2　NSAIDs潰瘍の治療と予防の考え方を知る
    　1．NSAIDs潰瘍の治療の実際を知る
    　2．NSAIDs潰瘍の予防の実際を知る

    Part 3　整形外科疾患における薬物療法とNSAIDsの位置づけをみる
    　1．変形性関節症に対する薬物療法におけるNSAIDsの位置づけ
    　2．リウマチ性疾患での使用の実際をみる
    　3．腰痛の疼痛管理での薬物療法の実際をみる
    　4．骨粗鬆症（骨粗鬆症関連骨折）での使用の実際をみる

    Part 4　NSAIDs潰瘍をくわしく知るためのQ&A
    　Q1　NSAIDsによる胃・十二指腸以外の消化管の影響
    　　　　を教えてください
    　Q2　ビスフォスフォネート製剤はNSAIDs潰瘍のリスクを
    　　　　上昇させますか？
    　Q3　PPIは骨折リスクを増大させるという報告がありますが、
    　　　　大丈夫ですか？
    　Q4　PPIの長期投与時の安全性については大丈夫ですか？

    Part 5　NSAIDs潰瘍の保険診療の注意点を知る
    　NSAIDs潰瘍の保険診療に関するQ&A

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

Part 1. 疼痛管理におけるNSAIDsの位置づけをみる～NSAIDs潰瘍の臨床的課題から治療および予防の意義を知る～

P.22 掲載の参考文献
1) 砥出勝雄:疼痛治療薬の基礎-痛みの基礎および新規疼痛ターゲット. 日薬理誌 128:321-325, 2006
Medical*Online
2) 大石了三:痛みの種類と鎮痛薬. 臨と研 84:762-765, 2007
Medical*Online
3) 益田律子:慢性疼痛の治療法-鎮痛補助薬. 治療 90:2081-2086, 2008
Medical*Online
4) Smolen JS, Landewe R, Breedveld FC et al:EULAR recommenda-tions for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 69:964-975, 2010
 
5) 楠夏子, 川合眞一:第1部 総論:NSAIDsの基礎知識 各薬剤の分類と特性(アセトアミノフェン含む). NSAIDsの選び方・使い方ハンドブック, 佐野統編, 羊土社, 東京, 2010, pp.26-31
 
6) 佐野統, 東直人:NSAIDs(非ステロイド性抗炎症鎮痛薬). よくわかるリウマチ治療薬の選び方・使い方-症例でわかる抗リウマチ薬・生物学的製剤の使い分け, 松原司編, 羊土社, 東京, 2011, pp.33-59
 
7) 佐野統:COX-2選択的阻害薬の消化管への安全性. COX-2阻害薬の適正使用, 佐野統編, フジメディカル出版, 大阪, 2012, pp.7-22
 
P.30 掲載の参考文献
1) Singh G, Rosen Ramey D:NSAID induced Gastrointestinal complica-tions:The ARAMIS perspective-1997. Arthritis, Rheumatism, and Aging Medical Information System. J Rheumatol Suppl 51:8-16, 1998
 
2) 塩川優一, 延永正, 斎藤輝信ほか:非ステロイド性抗炎症剤による上部消化管傷害に関する疫学調査. リウマチ 31:96-111, 1991
 
3) Miyake K, Kusunoki M, Shinji Y et al:Bisphosphonate increases risk of gastroduodenal ulcer in rheumatoid arthritis patients on long-term nonsteroidal antiinflammatory drug therapy. J Gastroenterol 44:113-120, 2009
PubMed
4) Wolfe MM, Lichtenstein DR, Singh G:Gastrointestinal toxicity of non-steroidal anti-inflammatory drugs. N Engl J Med 340:1888-1899, 1999
PubMed
5) Scheiman JM:Unmet needs in non-steroidal anti-inflammatory drug-induced upper gastrointestinal diseases. Drugs 66:15-21, 2006
PubMed

Part 2. NSAIDs潰瘍の治療と予防の考え方を知る

P.38 掲載の参考文献
1) 消化性潰瘍診療ガイドライン, 日本消化器病学会編, 南江堂, 東京, 2009
 
2) EBMに基づく胃潰瘍診療ガイドライン, 第2版, 胃潰瘍ガイドラインの適用と評価に関する研究班編, じほう, 東京, 2007
 
3) Wolfe MM, Lichtenstein DR, Singh G:Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 340:1888-1899, 1999
PubMed
4) Scheiman JM:Unmet needs in non-steroidal anti-inflammatory drug-induced upper gastrointestinal diseases. Drugs 66(suppl 1):15-21, 2006
 
5) Miyake K, Kusunoki M, Shinji Y et al:Bisphosphonate increases risk of gastroduodenal ulcer in rheumatoid arthritis patients on long-term nonsteroidal antiinflammatory drug therapy. J Gastroenterol 44:113-120, 2009
PubMed
6) Sakamoto C, Sugano K, Ota S et al:Case-control study on the asso-ciation of upper gastrointestinal bleeding and nonsteroidal anti-inflammatory drugs in Japan. Eur J Clin Pharmacol 62:765-772, 2006
 
P.46 掲載の参考文献
1) NSAIDs潰瘍:日本消化器病学会編, 消化性潰瘍診療ガイドライン, 南江堂, 東京, 2009, pp.92-113
 
2) Hooper L, Brown TJ, Elliott R et al:The effectiveness of five strate-gies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs:systematic review. BMJ 329:948-957, 2004
 
3) Rostom A, Dube C, Wells G et al:Prevention of NSAID-induced gas-troduodenal ulcers. Cochrane Database Syst Rev, 2002:CD002296
 
4) Park SH, Cho CS, Lee OY et al:Comparison of prevention of NSAID-induced gastrointestinal complications by rebamipide and misopros-tol:a randomized, multicenter, controlled trial-STORM study. J Clin Biochem Nutr 40:148-155, 2007
 
5) Vergara M, Catalan M, Gisbert JP et al:Meta-analysis:role of Heli-cobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol Ther 21:1411-1418, 2005
 
6) Silverstein FE, Faich G, Goldstein JL et al:Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoar-thritis and rheumatoid arthritis:the CLASS study:A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 284:1247-1255, 2000
 

Part 3. 整形外科疾患における薬物療法とNSAIDsの位置づけをみる

P.57 掲載の参考文献
1) Zhang W, Moskowitz RW, Nuki G et al:OARSI recommendations for the management of hip and knee osteoarthritis, part I:critical appraisal of existing treatment guidelines and systematic review of current research evidence. Osteoarthritis Cartilagre 15:981-1000, 2007
PubMed
2) Zhang W, Moskowitz RW, Nuki G et al:OARSI recommendations for the management of hip and knee osteoarthritis, Part II:OARSI evi-dence-based, expert consensus guidelines. Osteoarthritis Cartilage 16:137-162, 2008
 
3) 川口浩:変形性関節症・脊椎症-診断と治療の最前線- 変形性関節症の治療ガイドライン. Geriatr Med 48:307-314, 2010
 
4) Bjordal JM, Ljunggren AE, Klovning A et al:Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteo-arthritic knee pain:meta-analysis of randomised placebo controlled trials. BMJ 329:1317, 2004
 
5) Doi T, Akai M, Fujino K et al:Effect of nonsteroidal anti-inflamma-tory drug plasters for knee osteoarthritis in Japanese:a randomized controlled trial. Mod Rheumatol 20:24-33, 2010
 
6) Reijman M, Bierma-Zeinstra SM Pols HA et al:Is there an associa-tion between the use of different types of nonsteroidal antiinflamma-tory drugs and radiologic progression of osteoarthritis? The Rotter-dam Study. Arthritis Rheum 52:3137-3142, 2005
 
7) Louthrenoo W, Nilganuwong S, Aksaranugraha S et al:The efficacy, safety and carry-over effect of diacerein in the treatment of painful knee osteoarthritis:a randomised, double-blind, NSAID-controlled study. Osteoarthritis Cartilage 15:605-614, 2007
PubMed
P.63 掲載の参考文献
1) Shiokawa Y, Nobunaga M, Saito T et al:Epidemiology study on upper gastrointestinal lesions induced by non-steroidal anti-inflammatory drugs. Ryumachi 31:96-111, 1991
 
2) Fries JF, Murtagh KN, Bennett M et al:The rise and decline of non-steroidal antiinflammatory drug-associated gastropathy in rheuma-toid arthritis. Arthritis Rheum 50:2433-2440, 2004
 
3) Steen K, Nurmohamed MT, Visman I et al:Decreasing incidence of symptomatic gastrointestinal ulcers and ulcer complications in patients with rheumatoid arthritis. Ann Rheum Dis 67:256-259, 2008
PubMed
4) Wolfe F, Hawley DJ:The comparative risk and predictors of adverse gastrointestinal events in rheumatoid arthritis and osteoarthritis:a prospective 13 year study of 2131 patients. J Rheumatol 27:1668-1673, 2000
PubMed
5) Tanaka E, Singh G, Saito A et al:Prevalence of Helicobacter pylori infection and risk of upper gastrointestinal ulcer in patients with rheumatoid arthritis in Japan. Mod Rheunmatol 15:340-345, 2005
PubMed
6) Huang JQ, Sridhar S, Hunt RH:Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease:a meta-analysis. Lancet:159:14-22, 2002
 
7) Yamanaka H, Seto Y, Tanaka E et al:Management of rheumatoid arthritis:the 2012 perspective. Mod Rheumatol, 2012[Epub ahead of print]
 
P.71 掲載の参考文献
1) Deyo RA, Weinstein JN:Low back pain. N Engl J Med 344:363-370, 2001
PubMed
2) Pengel LH, Herbert RD, Maher CG et al:Acute low back pain:sys-tematic review of its prognosis. BMJ 127:323-325, 2003
 
3) Hestbaek L, Leboeuf-Yde C, Manniche C:Low back pain:what is the long-term course? A review of studies of general patient popula-tions, Eur Spine J 12:149-165, 2003
 
4) Roelofs PD, Deyo RA, Koes BW et al:Nonsteroidal anti-inflammatory drugs for low back pain:an updated Cochrane review. Spine 33: 1766-1774, 2008
PubMed
5) Schnitzer TJ. Ferraro A, Hunsche E et al:A comprehensive review of clinical trials on the efficacy and safety of drugs for the treatment of low back pain. J Pain Symptom Manage 28:72-95, 2004
PubMed
6) Chou R, Huffman LH;American Pain Society;American College of Physicians:Medications for acute and chronic low back pain:a review of the evidence for an American Pain Society/American Col-lege of Physicians clinical practice guideline. Ann Intern Med 147: 505-514, 2007
 
7) White AP, Arnold PM, Norvell DC et al:Pharmacologic management of chronic low back pain:synthesis of the evidence. Spine 36:S131-S143, 2011
PubMed
8) Romano CL, Romano D, Lacerenza M:Antineuropathic and antinoci-ceptive drugs combination in patients with chronic low back pain:a systematic review. Pain Res Treat 2012:154781, 2012
PubMed
P.78 掲載の参考文献
1) 骨粗鬆症の予防と治療ガイドライン2011年版, 骨粗鬆症の予防と治療ガイドライン作成委員会編, ライフサイエンス出版, 東京, 2011
 
2) Vestergaard P, Schwartz K, Pinholt EM et al:Gastric and esophagus events before and during treatment of osteoporosis. Calcif Tissue Int 86:110-115, 2010
PubMed
3) 重篤副作用疾患別対応マニュアル・消化性潰瘍(胃潰瘍, 十二指腸潰瘍, 急性胃粘膜病変, NSAIDs潰瘍), 厚生労働省, 2008(http://www.mhlw.go.jp/topics/2006/11/dl/tp1122-1g01.pdf)
 
4) Miyakoshi N, Kasukawa Y, Sasaki H et al:Impact of spinal kyphosis on gastroesophageal reflux disease symptoms in patients with osteo-porosis. Osteoporos Int 20:1193-1198, 2009
 
5) Graham DY, Malaty HM:Alendronate and naproxen are synergistic for development of gastric ulcers. Arch Intern Med 161:107-110, 2001
PubMed
6) Schjerning Olsen AM, Fosbol EL, Lindhardsen J et al:Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction:a nationwide cohort study. Circulation 123:2226-2235, 2011
PubMed

Part 4. NSAIDs潰瘍をくわしく知るためのQ & A

P.85 掲載の参考文献
1) Higuchi K, Umegaki E, Watanabe T et al:Present status and strategy of NSAIDs-induced small bowel injury. J Gastroenterol 44:879-888, 2009
PubMed
2) Umegaki E, Yoda Y, Tokioka S et al:Protective effect of roxatidine against indomethacin-induced small intestinal mucosal injury in rats. J Gastroenterol Hepatol 25 (suppl 1):S35-S40, 2010
 
3) Yoda Y, Takeuchi K, Kato S et al:Search for prophylactic drugs against NSAID-induced small intestinal lesions in rats. Gastroenterol-ogy 134(suppl 1):A528, 2008
 
4) Umegaki E, Morita E, Nouda S et al:Geranylgeranylacetone protects against NSAIDs-induced gastric and small intestinal mucosal injuries in healthy subjects:A prospective randomised study compared with famotidine. Gastrointest Endosc 71:AB363, 2010
 
5) 蔵原晃一, 松本主之, 飯田三雄ほか:NSAID起因性大腸病変の臨床像と内視鏡像. 胃と腸 42:1739-1749, 2007
 
P.90 掲載の参考文献
1) Graham DY, Malaty HM:Alendronate and naproxen are synergistic for development of gastric ulcers. Arch Intern Med 161:107-110, 2001
PubMed
2) Miyake K, Kusunoki M, Shinji Y et al:Bisphosphonate increases risk of gastroduodenal ulcer in rheumatoid arthritis patients on long-term non-steroidal anti-innammatory drug therapy. J Gastroenterol 44: 113-120, 2009
 
3) Laine L, Harper S, Simon T et al:A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthri-tis. Rofecoxib Osteoarthritis Endoscopy Study Group. Gastroenterol-ogy 117:776-783, 1999
 
4) Goldstein JL, Correa P, Zhao WW et al:Reduced incidence of gastro-duodenal ulcers with celecoxib, a rlovel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis. Am J Gastroenterol 96:1019-1027, 2001
 
5) Kearney PM, Baigent C, Godwin J et al:Do selective cyclo-oxygen-ase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of ran-domised trials. BMJ 332:1302-1308, 2006
 
P.94 掲載の参考文献
1) Yang YX, Metz DC:Safety of proton pump inhibitor exposure. Gas-troenterology 139:1115-1127, 2010
 
2) Hansen KE, Jones AN, Lindstrom MJ et al:Do proton pump inhibi-tors decrease calcium absorption? J Bone Miner Res 25:2786-2795, 2010
 
3) Gray SL, LaCroix AZ, Larson J et al:Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women:results from the Women's Health Initiative. Arch Intern Med 170:765-771, 2010
PubMed
4) Yamaguchi T, Sugimoto T, Yamauchi M et al:Multiple vertebral fractures are associated with refractory reflux esophagitis in post-menopausal women. J Bone Miner Metab 23:36-40, 2005
 
5) Moayyedi P, Cranney A:Hip fracture and proton pump inhibitor therapy:balancing the evidence for benefit and harm. Am J Gastro-enterol 103:2428-2431, 2008
 
P.99 掲載の参考文献
1) Sugano K, Matsumoto Y, Itabashi T et al:Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term low-dose aspirin therapy:results of a prospective, multicenter, dou-ble-blind, randomized, double-dummy, active-controlled trial. J Gas-troenterol 46:724-735, 2011
PubMed
2) Sugano K, Kontani T, Katsuo S et al:Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term non-steroidal anti-inflammatory drug(NSAID)therapy:results of a prospective, multicenter, double-blind, randomized, double-dummy, active-controlled trial. J Gastroenterol 47:540-552, 2012
PubMed
3) Johnstone J, Nerenberg K, Loeb M:Meta-analysis:proton pump inhibitor use and the risk of community-acquired pneumonia. Ali-ment pharmacol 11:1165-1177, 2010
 
4) Estborn L, Joelson S:Occurrence of community-acquired respiratory tract infection in patients receiving esomeprazole:retrospective analysis of adverse events in 31 clinical trials. Drug Saf 11:627-636, 2008
PubMed
5) Freston JW, Rose PA, Heller CA et al:Safety profile of Lansopra-zole:the US clinical trial experience. Drug Saf 20:195-205, 1999
 
6) Shimura S, Hamamoto N, Yoshino N et al:Diarrhea caused by proton pump inhibitor administration:comparisons among lansoprazole, rabeprazole, and omeprazole. Curr Ther Res Clin Exp 73:112-120, 2012
PubMed
7) Bavishi C, Dupont HL:Systematic review:the use of proton pump inhibitors and increased susceptibility to enteric infection. Aliment Pharmacol Ther 34:1269-1281, 2011
 
8) Deshpande A, Pant C, Pasupuleti V et al:Association between proton pump inhibitor therapy and Clostridium difficile infection in a meta-analysis. Clin Gastroenterol Hepatol 10:225-233, 2012
 

書評

最近チェックした商品履歴

Loading...